REFERENCES
- United States of America Before the Federal Trade Commission. In the matter of Eli Lilly and Company. Decision and Order, Docket No. C–3594.
- Bah() DA. A whole new world? Pharmaceutical responses to the managed care revolution. Food Drug Law J 1997;52: 83–98.
- CIBA Geneva Pharmaceuticals. Pharmacy benefit report: facts & figures. 1996 ed.
- Metzenbaum HM. Letter to the Federal Trade Commission, 31 July 1996.
- Health care costs set to rise: NC-IC. Market Letter 1997;24:14,
- Krulwich AS. The response to health care reform by the pharmaceutical industry. Food Drug Law J 1995;50:1–22.
- Shulman SR, DiCerbo PA, Ulcickas ME, Lasagna L. A survey of therapeu-tic substitution programs in ten Boston area hospitals. Drug Info J 1992;26:41–52.
- Nightingale SL. From the Food and Drug Administration. Request For in-formation on therapeutic switches. JAMA 1997;277:1029.
- Schulman KA, Rubenstein E, Abernathy DR at al. The effect of pharmaceu-tical benefit managers: is it being evaluated? Ann Intern Med 1996; 124:906–13.
- Krepling DH, Lipton HL, Collins T, Hertz KC. Assessment of the impact of pharmacy benefit managers. HCFA Master Contract HCFA-95-023/PK. Sep-tember ]30,1996.]